NCT06532383View on ClinicalTrials.gov

A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

January 16, 2025

Study Completion Date

January 16, 2025

Conditions
Healthy
Interventions
DRUG

PF-07940369

Bulk powder for extemporaneous preparation for oral solutions.

DRUG

Placebo

Bulk powder for extemporaneous preparation for oral solutions

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06532383 - A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults. | Biotech Hunter | Biotech Hunter